Skip to content
Screener

Alnylam Pharmaceuticals ALNY Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$28.44M-51.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$13.7M-38.9%
Moderna logo
ModernaMRNA
$284M+2.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$229K-34.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$15.54M+132%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$10.92M+20.6%

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$28.92B-48.5%
Enterprise value$27.47B-50.3%
P/E39.5×—
P/S6×-16.8×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%—
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062
Line itemJune 30, 2026December 31, 2025
Operating lease liabilities, net of current portion210,495225,087
Convertible debt1,010,9811,007,784
Liabilities related to the sale of future royalties and development funding, net of current portion1,461,5101,470,341
Other liabilities9,1527,594
Total liabilities4,204,6514,177,155
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025——

Cover / Front Matter

FAQ

What is Alnylam Pharmaceuticals's other non-current liabilities?
Alnylam Pharmaceuticals (ALNY) reported other non-current liabilities of $9.15M in Q2 2026.
How has Alnylam Pharmaceuticals's other non-current liabilities changed year-over-year?
Alnylam Pharmaceuticals's other non-current liabilities decreased by 16.3% year-over-year, from $10.93M to $9.15M.
What is the long-term trend for Alnylam Pharmaceuticals's other non-current liabilities?
Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's other non-current liabilities has grown at a -27.5% compound annual growth rate (CAGR), from $37.91M to $7.59M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Alnylam Pharmaceuticals's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude